Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-05-07
1998-06-02
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 72, A61K 3170
Patent
active
057600104
ABSTRACT:
This invention is directed to a novel method for treating humans with liver diseases or liver disorders with a macrolide antibiotic. Many different liver disorders can be treated with the claimed invention but this invention is specifically directed to treating nonalcoholic steatohepatitis, alcoholic hepatitis, and Reye's Syndrome. More specifically, this invention is directed to the oral administration of an erythromycin compound or an erythromycin derivative for the treatment of liver disease or liver disorders. The routes of administration can include oral, intramuscular, subcutaneous, transdermal, intravenous or other common routes of administering a drug to a patient. Alternate routes for patients diagnosed with alcoholic hepatitis or Reye's Syndrome are extremely important as oral administration would not be effective due to the patient's clinical symptoms. Most specifically, this invention teaches the novel oral administration of clarithromycin, troleandomycin, erythromycin, or azithromycin for treating human patients with liver disease or liver disorders, including but not limited to nonalcoholic steatohepatitis, alcoholic hepatitis, and Reye's Syndrome.
REFERENCES:
patent: 4482540 (1984-11-01), Gordon et al.
Physician's Desk Reference.RTM., pp. 421-423, 425-427, 449, 651, 935, 937, 1841, 2102, and 2419 (1995).
Peter B. Gregory, M.D.; "Cirrhosis of the Liver"; Mar. 1995; Scientific American, Inc.
Achord, J.L., Review of Alcoholic Hepatitis, and Its Treatment, The American Journal of Gastroenterology, 88(11):1822-1828 (1993).
Alpers, D.H., et al., Fatty Liver: Biochemical and Clinical Aspects, Diseases of the Liver, 4th Ed., Chap. 25, pp. 815-829, 1224-1228 (1975).
Bacon, B.R., et al., Nonalcoholic Steatohepatitis: An Expanded Clinical Entity, Gastroenterology, 107:1103-1109 (1994).
Cohen, et al., The SGOT/SGPT Ratio: An Indicator of Alcoholic Liver Disease, Dig. Dis. Sci., 24:835-838 (1979).
Goldberg, et al., VA Cooperative Study on Alcoholic Hepatitis IV, American Journal of Gastroenterology, 81:1029-1034 (1986).
Gregory, P.G., Cirrhosis of the Liver in Scientific American Medicine for Gastroenterology, pp. 1-18 (1995).
Isselbacher, K.J., et al., Infiltrative and Metabolic Disease Affecting the Liver in Harrison's Principles of Internal Medicine eds. Brawnald, E. et al., pp. 1353-1354 (1988).
Ludwig, et al., Nonalcoholic Steatohepatitis. Mayo Clinic Experiences With A Hitherto Unnamed Disease, Mayo Clinical Proceedings, 55:434-438 (1980).
Metropolitan Height and Weight Tables, Metropolitan Life Insurance Company, New York (1983).
Physicians' Desk Reference.RTM., pp. 405-408, 1789-1791 (1994).
Physicians' Desk Reference.RTM., pp. 421-423, 425-427, 449, 651, 935, 937, 1841, and 2102 (1995).
Reye, et al., Encephalopathy and fatty degeneration of the viscera, Lancet, 2:749 (1963).
Schubert, et al., Encephalopathy and Fatty Liver (Reye's Syndrome), In: Popper, H., et al., (Eds.): Progress in Liver Diseases, 4th Ed., Grune and Stratton, Inc., New York, Chap. 28, pp. 489-510 (1972).
LandOfFree
Method of treating liver disorders with a macrolide antibiotic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating liver disorders with a macrolide antibiotic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating liver disorders with a macrolide antibiotic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459843